ID   HCC-1.2
AC   CVCL_0C53
SY   HCC.1.2; HCC1.2; 1.2; 3P; 3p
DR   ChEMBL-Cells; CHEMBL4295407
DR   ChEMBL-Targets; CHEMBL4296419
DR   Cosmic; 1628382
DR   Cosmic; 2162520
DR   Cosmic; 2162521
DR   PubChem_Cell_line; CVCL_0C53
DR   Wikidata; Q54881505
RX   PubMed=18594539;
RX   PubMed=21364009;
RX   PubMed=23887712;
WW   https://lccl.zucmanlab.com/hcc/cellLines/HCC.1.2
CC   Miscellaneous: Direct author submission of STR profile from Rohr-Udilova N.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 14,16
ST   D21S11: 28,29
ST   D3S1358: 15,16
ST   D5S818: 10,13
ST   D7S820: 9,10
ST   D8S1179: 11,13
ST   FGA: 20
ST   Penta D: 12,13
ST   Penta E: 10,12
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0C42 ! BLC-1
OI   CVCL_0C52 ! HCC-1.1
OI   CVCL_0C47 ! MF-1 [Human]
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 10
//
RX   PubMed=18594539; DOI=10.1038/sj.bjc.6604440;
RA   Sagmeister S., Eisenbauer M., Pirker C., Mohr T., Holzmann K.,
RA   Zwickl H., Bichler C., Kandioler-Eckersberger D., Wrba F., Mikulits W.,
RA   Gerner C., Shehata M., Majdic O., Streubel B., Berger W., Micksche M.,
RA   Zatloukal K., Schulte-Hermann R., Grasl-Kraupp B.;
RT   "New cellular tools reveal complex epithelial-mesenchymal interactions
RT   in hepatocarcinogenesis.";
RL   Br. J. Cancer 99:151-159(2008).
//
RX   PubMed=21364009; DOI=10.1158/1535-7163.MCT-10-0917;
RA   van Zijl F., Mall S., Machat G., Pirker C., Zeillinger R.,
RA   Weinhaeusel A., Bilban M., Berger W., Mikulits W.;
RT   "A human model of epithelial to mesenchymal transition to monitor drug
RT   efficacy in hepatocellular carcinoma progression.";
RL   Mol. Cancer Ther. 10:850-860(2011).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//